AXL (R499C)
Sign in to save this workspaceAXL · Variant type: point · HGVS: p.R499C
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Gilteritinib | 98.0% | 2.0% | 88.97 |
| 2 | Cabozantinib | 95.9% | 4.1% | 92.73 |
| 3 | Neratinib | 94.1% | 5.9% | 93.18 |
| 4 | Crizotinib | 93.5% | 6.5% | 91.39 |
| 5 | Brigatinib | 93.5% | 6.5% | 82.96 |
| 6 | Sunitinib | 93.3% | 6.7% | 91.73 |
| 7 | Selpercatinib | 92.8% | 7.2% | 96.72 |
| 8 | Bosutinib | 88.5% | 11.5% | 87.22 |
| 9 | Pacritinib | 87.3% | 12.7% | 88.64 |
| 10 | Nintedanib | 87.0% | 13.0% | 90.23 |
| 11 | Alectinib | 85.3% | 14.7% | 95.49 |
| 12 | Pralsetinib | 81.1% | 18.9% | 93.43 |
| 13 | Lazertinib | 79.5% | 20.5% | 97.47 |
| 14 | Entrectinib | 79.4% | 20.6% | 93.69 |
| 15 | Fedratinib | 78.9% | 21.1% | 96.21 |
| 16 | Axitinib | 75.3% | 24.7% | 93.23 |
| 17 | Tivozanib | 74.2% | 25.8% | 92.42 |
| 18 | Repotrectinib | 69.6% | 30.4% | 84.21 |
| 19 | Tepotinib | 66.0% | 34.0% | 99.75 |
| 20 | Defactinib | 65.2% | 34.8% | 92.68 |
| 21 | Ponatinib | 60.5% | 39.5% | 78.23 |
| 22 | Fostamatinib | 59.9% | 40.1% | 96.74 |
| 23 | Vandetanib | 46.3% | 53.7% | 95.74 |
| 24 | Afatinib | 37.1% | 62.9% | 98.50 |
| 25 | Vemurafenib | 35.6% | 64.4% | 96.49 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Gilteritinib | 98.0% | 98.7% | -0.7% |
| Cabozantinib | 95.9% | 95.9% | -0.0% |
| Neratinib | 94.1% | 96.3% | -2.2% |
| Crizotinib | 93.5% | 97.1% | -3.6% |
| Brigatinib | 93.5% | 85.3% | +8.2% |
| Sunitinib | 93.3% | 90.6% | +2.8% |
| Selpercatinib | 92.8% | 85.2% | +7.6% |
| Bosutinib | 88.5% | 89.9% | -1.4% |
| Pacritinib | 87.3% | 89.8% | -2.5% |
| Nintedanib | 87.0% | 79.5% | +7.4% |
| Alectinib | 85.3% | 75.8% | +9.5% |
| Pralsetinib | 81.1% | 76.7% | +4.4% |
| Lazertinib | 79.5% | 81.1% | -1.6% |
| Entrectinib | 79.4% | 73.6% | +5.8% |
| Fedratinib | 78.9% | 76.3% | +2.6% |
| Axitinib | 75.3% | 64.9% | +10.4% |
| Tivozanib | 74.2% | 72.8% | +1.4% |
| Repotrectinib | 69.6% | 77.8% | -8.2% |
| Tepotinib | 66.0% | 69.6% | -3.5% |
| Defactinib | 65.2% | 69.9% | -4.7% |
| Ponatinib | 60.5% | — | — |
| Fostamatinib | 59.9% | — | — |
| Vandetanib | 46.3% | — | — |
| Afatinib | 37.1% | — | — |
| Vemurafenib | 35.6% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_skin | Skin | ref |
| carcinoma_large_intestine | Large Intestine | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.1ms